Financhill
Sell
41

EDAP Quote, Financials, Valuation and Earnings

Last price:
$3.00
Seasonality move :
24.85%
Day range:
$2.82 - $3.04
52-week range:
$1.21 - $3.44
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.58x
P/B ratio:
4.05x
Volume:
13.4K
Avg. volume:
58.2K
1-year change:
35.61%
Market cap:
$111.1M
Revenue:
$69.4M
EPS (TTM):
-$0.58

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
EDAP
EDAP TMS SA
$15M -$0.26 -5.42% -134.66% $5.83
AKTX
Akari Therapeutics Plc
-- -$0.11 -- -53.67% $3.53
ASND
Ascendis Pharma A/S
$245M -$0.18 54.04% -76.86% $262.82
CLLS
Cellectis SA
$9.6M -$0.10 -5.7% -56.58% $7.20
DBVT
DBV Technologies SA
$889.9K -$0.34 -- -80.11% $40.03
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
EDAP
EDAP TMS SA
$2.97 $5.83 $111.1M -- $0.00 0% 1.58x
AKTX
Akari Therapeutics Plc
$0.27 $3.53 $9.6M -- $0.00 0% --
ASND
Ascendis Pharma A/S
$212.84 $262.82 $13B -- $0.00 0% 17.80x
CLLS
Cellectis SA
$4.84 $7.20 $485.6M -- $0.00 0% 6.02x
DBVT
DBV Technologies SA
$19.03 $40.03 $520.7M -- $0.00 0% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
EDAP
EDAP TMS SA
24.46% 0.744 10.36% 0.94x
AKTX
Akari Therapeutics Plc
8.54% -2.620 6.43% 0.16x
ASND
Ascendis Pharma A/S
127.22% -0.522 7.87% 0.68x
CLLS
Cellectis SA
54.27% 0.665 41.7% 1.35x
DBVT
DBV Technologies SA
23.24% -1.892 5.85% 1.41x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
EDAP
EDAP TMS SA
$7M -$5.8M -45.27% -56.97% -35.49% -$5.2M
AKTX
Akari Therapeutics Plc
-- -$2.2M -82.27% -91.86% -- -$2.1M
ASND
Ascendis Pharma A/S
$219.4M $12.9M -34.4% -880.05% 5.15% $1.3M
CLLS
Cellectis SA
$30M $5.9M -15.69% -31.08% 16.76% -$4M
DBVT
DBV Technologies SA
-$4.3M -$36.9M -211.46% -280.59% -- -$32.5M

EDAP TMS SA vs. Competitors

  • Which has Higher Returns EDAP or AKTX?

    Akari Therapeutics Plc has a net margin of -36.13% compared to EDAP TMS SA's net margin of --. EDAP TMS SA's return on equity of -56.97% beat Akari Therapeutics Plc's return on equity of -91.86%.

    Company Gross Margin Earnings Per Share Invested Capital
    EDAP
    EDAP TMS SA
    43.02% -$0.16 $36.3M
    AKTX
    Akari Therapeutics Plc
    -- -$0.19 $24.8M
  • What do Analysts Say About EDAP or AKTX?

    EDAP TMS SA has a consensus price target of $5.83, signalling upside risk potential of 96.4%. On the other hand Akari Therapeutics Plc has an analysts' consensus of $3.53 which suggests that it could grow by 1340.41%. Given that Akari Therapeutics Plc has higher upside potential than EDAP TMS SA, analysts believe Akari Therapeutics Plc is more attractive than EDAP TMS SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    EDAP
    EDAP TMS SA
    1 2 0
    AKTX
    Akari Therapeutics Plc
    2 0 0
  • Is EDAP or AKTX More Risky?

    EDAP TMS SA has a beta of -0.152, which suggesting that the stock is 115.246% less volatile than S&P 500. In comparison Akari Therapeutics Plc has a beta of 0.279, suggesting its less volatile than the S&P 500 by 72.076%.

  • Which is a Better Dividend Stock EDAP or AKTX?

    EDAP TMS SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akari Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EDAP TMS SA pays -- of its earnings as a dividend. Akari Therapeutics Plc pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EDAP or AKTX?

    EDAP TMS SA quarterly revenues are $16.2M, which are larger than Akari Therapeutics Plc quarterly revenues of --. EDAP TMS SA's net income of -$5.9M is higher than Akari Therapeutics Plc's net income of -$6.4M. Notably, EDAP TMS SA's price-to-earnings ratio is -- while Akari Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EDAP TMS SA is 1.58x versus -- for Akari Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EDAP
    EDAP TMS SA
    1.58x -- $16.2M -$5.9M
    AKTX
    Akari Therapeutics Plc
    -- -- -- -$6.4M
  • Which has Higher Returns EDAP or ASND?

    Ascendis Pharma A/S has a net margin of -36.13% compared to EDAP TMS SA's net margin of -28.55%. EDAP TMS SA's return on equity of -56.97% beat Ascendis Pharma A/S's return on equity of -880.05%.

    Company Gross Margin Earnings Per Share Invested Capital
    EDAP
    EDAP TMS SA
    43.02% -$0.16 $36.3M
    ASND
    Ascendis Pharma A/S
    87.87% -$1.17 $751.5M
  • What do Analysts Say About EDAP or ASND?

    EDAP TMS SA has a consensus price target of $5.83, signalling upside risk potential of 96.4%. On the other hand Ascendis Pharma A/S has an analysts' consensus of $262.82 which suggests that it could grow by 24.92%. Given that EDAP TMS SA has higher upside potential than Ascendis Pharma A/S, analysts believe EDAP TMS SA is more attractive than Ascendis Pharma A/S.

    Company Buy Ratings Hold Ratings Sell Ratings
    EDAP
    EDAP TMS SA
    1 2 0
    ASND
    Ascendis Pharma A/S
    13 0 0
  • Is EDAP or ASND More Risky?

    EDAP TMS SA has a beta of -0.152, which suggesting that the stock is 115.246% less volatile than S&P 500. In comparison Ascendis Pharma A/S has a beta of 0.448, suggesting its less volatile than the S&P 500 by 55.182%.

  • Which is a Better Dividend Stock EDAP or ASND?

    EDAP TMS SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ascendis Pharma A/S offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EDAP TMS SA pays -- of its earnings as a dividend. Ascendis Pharma A/S pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EDAP or ASND?

    EDAP TMS SA quarterly revenues are $16.2M, which are smaller than Ascendis Pharma A/S quarterly revenues of $249.6M. EDAP TMS SA's net income of -$5.9M is higher than Ascendis Pharma A/S's net income of -$71.3M. Notably, EDAP TMS SA's price-to-earnings ratio is -- while Ascendis Pharma A/S's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EDAP TMS SA is 1.58x versus 17.80x for Ascendis Pharma A/S. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EDAP
    EDAP TMS SA
    1.58x -- $16.2M -$5.9M
    ASND
    Ascendis Pharma A/S
    17.80x -- $249.6M -$71.3M
  • Which has Higher Returns EDAP or CLLS?

    Cellectis SA has a net margin of -36.13% compared to EDAP TMS SA's net margin of 1.68%. EDAP TMS SA's return on equity of -56.97% beat Cellectis SA's return on equity of -31.08%.

    Company Gross Margin Earnings Per Share Invested Capital
    EDAP
    EDAP TMS SA
    43.02% -$0.16 $36.3M
    CLLS
    Cellectis SA
    85.76% $0.01 $219.7M
  • What do Analysts Say About EDAP or CLLS?

    EDAP TMS SA has a consensus price target of $5.83, signalling upside risk potential of 96.4%. On the other hand Cellectis SA has an analysts' consensus of $7.20 which suggests that it could grow by 48.76%. Given that EDAP TMS SA has higher upside potential than Cellectis SA, analysts believe EDAP TMS SA is more attractive than Cellectis SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    EDAP
    EDAP TMS SA
    1 2 0
    CLLS
    Cellectis SA
    2 2 0
  • Is EDAP or CLLS More Risky?

    EDAP TMS SA has a beta of -0.152, which suggesting that the stock is 115.246% less volatile than S&P 500. In comparison Cellectis SA has a beta of 2.818, suggesting its more volatile than the S&P 500 by 181.784%.

  • Which is a Better Dividend Stock EDAP or CLLS?

    EDAP TMS SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EDAP TMS SA pays -- of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EDAP or CLLS?

    EDAP TMS SA quarterly revenues are $16.2M, which are smaller than Cellectis SA quarterly revenues of $35M. EDAP TMS SA's net income of -$5.9M is lower than Cellectis SA's net income of $586.4K. Notably, EDAP TMS SA's price-to-earnings ratio is -- while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EDAP TMS SA is 1.58x versus 6.02x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EDAP
    EDAP TMS SA
    1.58x -- $16.2M -$5.9M
    CLLS
    Cellectis SA
    6.02x -- $35M $586.4K
  • Which has Higher Returns EDAP or DBVT?

    DBV Technologies SA has a net margin of -36.13% compared to EDAP TMS SA's net margin of --. EDAP TMS SA's return on equity of -56.97% beat DBV Technologies SA's return on equity of -280.59%.

    Company Gross Margin Earnings Per Share Invested Capital
    EDAP
    EDAP TMS SA
    43.02% -$0.16 $36.3M
    DBVT
    DBV Technologies SA
    -- -$1.21 $68.9M
  • What do Analysts Say About EDAP or DBVT?

    EDAP TMS SA has a consensus price target of $5.83, signalling upside risk potential of 96.4%. On the other hand DBV Technologies SA has an analysts' consensus of $40.03 which suggests that it could grow by 109.38%. Given that DBV Technologies SA has higher upside potential than EDAP TMS SA, analysts believe DBV Technologies SA is more attractive than EDAP TMS SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    EDAP
    EDAP TMS SA
    1 2 0
    DBVT
    DBV Technologies SA
    4 0 1
  • Is EDAP or DBVT More Risky?

    EDAP TMS SA has a beta of -0.152, which suggesting that the stock is 115.246% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -1.102, suggesting its less volatile than the S&P 500 by 210.179%.

  • Which is a Better Dividend Stock EDAP or DBVT?

    EDAP TMS SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EDAP TMS SA pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EDAP or DBVT?

    EDAP TMS SA quarterly revenues are $16.2M, which are larger than DBV Technologies SA quarterly revenues of --. EDAP TMS SA's net income of -$5.9M is higher than DBV Technologies SA's net income of -$33M. Notably, EDAP TMS SA's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EDAP TMS SA is 1.58x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EDAP
    EDAP TMS SA
    1.58x -- $16.2M -$5.9M
    DBVT
    DBV Technologies SA
    -- -- -- -$33M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is DocuSign Stock Undervalued?
Is DocuSign Stock Undervalued?

Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…

Is SentinelOne Stock Undervalued?
Is SentinelOne Stock Undervalued?

Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…

Is Broadcom Stock on Sale?
Is Broadcom Stock on Sale?

Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…

Stock Ideas

Buy
57
Is NVDA Stock a Buy?

Market Cap: $4.6T
P/E Ratio: 64x

Buy
55
Is AAPL Stock a Buy?

Market Cap: $4T
P/E Ratio: 37x

Buy
61
Is GOOG Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 39x

Alerts

Buy
87
HUT alert for Dec 25

Hut 8 Corp. [HUT] is up 0.65% over the past day.

Buy
80
TVTX alert for Dec 25

Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.

Buy
60
GPCR alert for Dec 25

Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock